Enzo | GenomeWeb


The company also reported FY2016 revenues rose 5 percent year over year, despite a dip in product revenues for the year.

Illumina follows Agilent, Life Technologies, Affymetrix, Siemens, and Luminex in settling lawsuits alleging infringement of US Patent No 7,064,197.

Contributing to the growth was a 16 percent increase in revenues from Enzo's clinical lab services division, which includes its molecular diagnostics offerings.

The AmpiProbe Candidiasis test identifies five common species of Candida bacteria from a vaginal swab, and is the third test from Enzo to be approved in NY state.

Thermo Fisher Scientific subsidiary Life Technologies will pay Enzo $35 million for infringing on two patents pertaining to labeled nucleotides and nucleic acids.

The company said higher demand for molecular diagnostics spurred a 19 percent increase in its clinical lab revenues.

Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.

The investment firm had sought to place two candidates on Enzo's board but withdrew its proxy contest after failing to gain ISS's endorsement.

The Enzo shareholder issued an open letter stating its concern about the company's stock performance.


In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.